1. Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
- Author
-
Ricardo Roa-Chamorro, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Fernando Jaén-Águila, Pablo González-Bustos, Miguel Ángel Rodríguez-Gil, and Juan Diego Mediavilla-García
- Subjects
Medicine ,Science - Abstract
Abstract Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic discontinuation in selected individuals could be a strategy in order to prevent the development of ACVD. Observational study of patients with CML under nilotinib treatment. The lipid values were gathered before starting with nilotinib and after 3 months. Such values were also measured before discontinuation in patients who suspended nilotinib treatment, as well as 3 and 12 months later. 32 patients were included, 19 of them treated in monotherapy with nilotinib. The concentrations of total cholesterol and low-density lipoproteins (LDL) increased significantly after 3 months of treatment (27.29 mg/dL ± 22.88, p
- Published
- 2023
- Full Text
- View/download PDF